2015靶向治疗新进展张力教授课件.pptVIP

张 力 ;2015 ASCO 肺癌分子靶向治疗新进展;晚期NSCLC治疗已经进入到基因分型的个体化时代;EGFR-TKI的进展;比较阿法替尼与厄洛替尼用于晚期肺鳞癌含铂化疗失败后的二线治疗：来自全球III期研究LUX-Lung(LL8)的生存数据(OS);Presented By Jean-Charles Soria at 2015 ASCO Annual Meeting;LUX-Lung 8：PFS (独立评估)更新了所有随机入组患者的数据(n=795);Presented By Jean-Charles Soria at 2015 ASCO Annual Meeting;Presented By Jean-Charles Soria at 2015 ASCO Annual Meeting;Presented By Jean-Charles Soria at 2015 ASCO Annual Meeting;突变选择性EGFR抑制剂AZD9291作为一线治疗EGFR突变阳性晚期非小细胞肺癌（NSCLC）：来自一项I期扩展队列的结果;Presented By Suresh Ramalingam at 2015 ASCO Annual Meeting;Presented By Suresh Ramalingam at 2015 ASCO Annual Meet